Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer

Stopped Enrollment was slow, due to competition with the many other clinical trials for the same patient population, which led to the decision to end enrollment in the trial.

Conditions

• Non Small Cell Lung Cancer

Interventions

• BIOLOGICAL: quaratusugene ozeplasmid
• DRUG: pembrolizumab
• DRUG: docetaxel
• DRUG: ramucirumab
• DRUG: Investigator's Treatment of Choice

Sponsor

Genprex, Inc.